(NASDAQ: HRTX) Heron Therapeutics's forecast annual revenue growth rate of 11.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.8%.
Heron Therapeutics's revenue in 2026 is $150,712,000.On average, 5 Wall Street analysts forecast HRTX's revenue for 2026 to be $31,980,642,186, with the lowest HRTX revenue forecast at $29,345,873,370, and the highest HRTX revenue forecast at $34,403,418,109. On average, 4 Wall Street analysts forecast HRTX's revenue for 2027 to be $33,960,504,386, with the lowest HRTX revenue forecast at $28,435,439,605, and the highest HRTX revenue forecast at $39,451,498,881.
In 2028, HRTX is forecast to generate $39,036,977,063 in revenue, with the lowest revenue forecast at $31,700,508,720 and the highest revenue forecast at $46,407,515,691.